
Influenza
Latest News

Latest Videos

Podcasts
More News

A phylodynamic analysis combining Arizona wild bird surveillance with national sequence data found the H5N1 D1.1 genotype spread in a stepwise pattern among adjacent US flyways during fall 2024, with limited direct exchange between the Pacific and Atlantic flyways.

Despite competing national crises drawing attention elsewhere, experts warn that the ongoing H5N1 avian influenza outbreak in birds, cattle, and humans in the United States highlights critical gaps in surveillance, worker protections, and pandemic preparedness that must be addressed to prevent a future pandemic.

The FDA has approved the first generic version of baloxavir marboxil (Xofluza), expanding access to a single-dose oral treatment and postexposure prophylaxis option for influenza in patients 5 years or older.

New data on flu vaccine for children counter the contention that a lack of contemporaneous randomized data justifies its removal from recommended annual immunizations.

Results from a large population-based study found that receiving influenza and pertussis vaccines on the same day during pregnancy does not increase the risk of adverse maternal, birth, or neonatal outcomes compared with pertussis vaccination alone.

Investigators identified behavioral determinants of being tested for pathogen exposure, in interviewing a focus group presented with a hypothetical avian influenza outbreak.

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted for a trivalent vaccine composition for use in the US, protecting against influenza A (H1N1 and H3N2) and influenza B (Victoria lineage).

Moderna has cleared a major regulatory milestone in Europe after the EMA’s CHMP recommended approval of mRNA-1083 (mCOMBRIAX), the world’s first combined influenza and COVID-19 vaccine for adults aged 50 and older.

Traws Pharma announced positive phase 2 results showing its investigational COVID-19 antiviral ratutrelvir as a possible alternative to Paxlovid, including for ineligible patients, while advancing tivoxavir marboxil as a once-monthly oral prophylactic for seasonal influenza.

The FDA declined to review Moderna’s mRNA flu vaccine application for its mRNA-1010 product, and based its decision on it choice of comparator in a phase 3 trial, despite the absence of safety or efficacy concerns and prior FDA agreement on the study design. Moderna requested a meeting to understand the path forward with the vaccine.

The American Academy of Pediatrics (AAP) has published its 2026 immunization schedule, reaffirming routine vaccination to protect children and adolescents against 18 preventable diseases.

The federal agency gave the nod for Acon Laboratories’ Flowflex Plus RSV + Flu A/B + COVID 4-in-1 test that can detect all those respiratory viruses in a single test, which is indicated for use in both adults and children as young as 6 months.

With rates of influenza vaccination in decline, two health systems evaluated interventions for prompting clinicians to order, and patients to obtain flu shots.

CDC surveillance shows sharp week-over-week increases in influenza test positivity, outpatient illness, and hospital admissions, with A(H3N2) continuing to predominate nationwide.

Early 2025 Influenza Vaccination Trends Following Prior Season and H3N2 Start
New Centers for Disease Control and Prevention (CDC) data show rising early-season influenza activity, moderate 2024–2025 vaccine effectiveness, and updated 2025–2026 recommendations that include trivalent, thimerosal-free single-dose formulations and expanded access to FluMist.

This is the first human ever known to be infected with the H5N5 strain. The infected patient was from Washington state, and was undergoing treatment for H5N5 (avian influenza) when the individual died last week.

Large international study reports higher A-strain protection and acceptable safety profile for quadrivalent RNA influenza vaccine.

A review of vaccine safety and effectiveness conducted by the Vaccine Integrity Project, independent of the CDC's ACIP, reflects its stated purpose as "dedicated to safeguarding vaccine use in the US."

Prescribing of antiviral medication for children at risk of severe influenza decreased in COVID-19 pandemic despite unchanged treatment guidelines.

Bird migration has started. Surveillance and early detection are key, especially as it relates to H5N1 and predicting this year's respiratory virus season.

Multicenter study will measure efficacy, safety, and immunogenicity in adults 18–59 across Europe.

Record-high 127.1/100,000 hospitalizations with co-circulating influenza A strains and similar in-hospital severity to prior years.

Corner Therapeutics says its "hyperactivator" adjuvant technology can offer protection against all virus strains.

Results from a Danish trial of more than 330,000 adults 65 years or older found high- and standard-dose influenza vaccines had similar effectiveness against influenza or pneumonia-related hospitalizations.

This comes after the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) made the recommendation to remove the vaccine preservative.


















































































































































































